Pretreatment with TNF inhibitors may improve outcomes of combination cancer immunotherapy

This study proposes a new therapeutic approach against cancer that dissociates efficacy and toxicity in the use of combined immunotherapy in animal models. This clinical strategy consists of blocking TNF protein while applying combination immunotherapy treatment (inhibition therapy of PD-1 and CTLA-4, other proteins that ‘slow down’ the immune response).

Leave a Reply

Your email address will not be published. Required fields are marked *